Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098865 · ClinicalTrials.gov registry record · Phase 2
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT00098865 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 15 participants.
The verdict
NCT00098865, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with temozolomide may kill more tumor cells. PURPOSE: This phase II trial is studying the effectiveness of combining thalidomide with temozolomide in treating young patients who have relapsed or progressive brain tumors or recurrent neuroblastoma.
Interventions
- DRUG temozolomide
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2002-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00098865
The ClinicalTrials.gov registry entry for NCT00098865 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00098865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00098865 about?
NCT00098865 is a clinical study titled "Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma". RATIONALE: Thalidomide may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining thalidomide with temozolomide may kill more tumor cells. P...
What is the current status of trial NCT00098865?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2002-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00098865?
The interventions under investigation include: temozolomide (DRUG), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00098865?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.